Cargando…
Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
New drugs, including immune checkpoint inhibitors and targeted therapy, have changed the prognosis in a subset of patients with advanced lung cancer, and are now actively investigated in a number of trials with neoadjuvant and adjuvant regimens. However, no phase III randomized studies were publishe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622767/ https://www.ncbi.nlm.nih.gov/pubmed/34830123 http://dx.doi.org/10.3390/ijms222212244 |
_version_ | 1784605771246338048 |
---|---|
author | Marjanski, Tomasz Dziedzic, Robert Kowalczyk, Anna Rzyman, Witold |
author_facet | Marjanski, Tomasz Dziedzic, Robert Kowalczyk, Anna Rzyman, Witold |
author_sort | Marjanski, Tomasz |
collection | PubMed |
description | New drugs, including immune checkpoint inhibitors and targeted therapy, have changed the prognosis in a subset of patients with advanced lung cancer, and are now actively investigated in a number of trials with neoadjuvant and adjuvant regimens. However, no phase III randomized studies were published yet. The current narrative review proves that targeted therapies are safe in neoadjuvant approach. Unsurprisingly, administration of therapy is related to an acceptable toxicity profile. Severe adverse events’ rate that rarely compromises outcomes of patients with advanced lung cancer is not that commonly accepted in early lung cancer as it may lead to missing the chance of curative surgery. Among those complications, the most important factors that may limit the use of targeted therapies are severe respiratory adverse events precluding the resection occurring after treatment with some anaplastic lymphoma kinase and rarely after epidermal growth factor receptor tyrosine kinase inhibitors. At this point, in the presented literature assessing the feasibility of neoadjuvant therapies with anaplastic lymphoma kinase and epidermal growth factor receptor tyrosine kinase inhibitors, we did not find any unexpected intraoperative events that would be of special interest to a thoracic surgeon. Moreover, the postoperative course was associated with typical rate of complications. |
format | Online Article Text |
id | pubmed-8622767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86227672021-11-27 Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review Marjanski, Tomasz Dziedzic, Robert Kowalczyk, Anna Rzyman, Witold Int J Mol Sci Review New drugs, including immune checkpoint inhibitors and targeted therapy, have changed the prognosis in a subset of patients with advanced lung cancer, and are now actively investigated in a number of trials with neoadjuvant and adjuvant regimens. However, no phase III randomized studies were published yet. The current narrative review proves that targeted therapies are safe in neoadjuvant approach. Unsurprisingly, administration of therapy is related to an acceptable toxicity profile. Severe adverse events’ rate that rarely compromises outcomes of patients with advanced lung cancer is not that commonly accepted in early lung cancer as it may lead to missing the chance of curative surgery. Among those complications, the most important factors that may limit the use of targeted therapies are severe respiratory adverse events precluding the resection occurring after treatment with some anaplastic lymphoma kinase and rarely after epidermal growth factor receptor tyrosine kinase inhibitors. At this point, in the presented literature assessing the feasibility of neoadjuvant therapies with anaplastic lymphoma kinase and epidermal growth factor receptor tyrosine kinase inhibitors, we did not find any unexpected intraoperative events that would be of special interest to a thoracic surgeon. Moreover, the postoperative course was associated with typical rate of complications. MDPI 2021-11-12 /pmc/articles/PMC8622767/ /pubmed/34830123 http://dx.doi.org/10.3390/ijms222212244 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Marjanski, Tomasz Dziedzic, Robert Kowalczyk, Anna Rzyman, Witold Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review |
title | Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review |
title_full | Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review |
title_fullStr | Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review |
title_full_unstemmed | Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review |
title_short | Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review |
title_sort | safety of surgery after neoadjuvant targeted therapies in non-small cell lung cancer: a narrative review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622767/ https://www.ncbi.nlm.nih.gov/pubmed/34830123 http://dx.doi.org/10.3390/ijms222212244 |
work_keys_str_mv | AT marjanskitomasz safetyofsurgeryafterneoadjuvanttargetedtherapiesinnonsmallcelllungcanceranarrativereview AT dziedzicrobert safetyofsurgeryafterneoadjuvanttargetedtherapiesinnonsmallcelllungcanceranarrativereview AT kowalczykanna safetyofsurgeryafterneoadjuvanttargetedtherapiesinnonsmallcelllungcanceranarrativereview AT rzymanwitold safetyofsurgeryafterneoadjuvanttargetedtherapiesinnonsmallcelllungcanceranarrativereview |